16+
Major trials tracked
An oral GLP-1 candidate against an injectable GLP-1 standard
Orforglipron vs semaglutide: trial pipelines compared
A side-by-side view of the orforglipron and semaglutide clinical trial pipelines, built from live ClinicalTrials.gov data and refreshed daily. ClinicalTrials.gov lists 16+ phase 2–4 trials for orforglipron and 16+ for semaglutide. Add up to three more drugs to widen the comparison.
orforglipron (16) vs semaglutide (16)18 active2014–2033
orforglipronsemaglutide
'14
'16
'18
'20
'22
'24
'26
'28
'30
'32
orforglipron
ACHIEVE-4P3
ATTAIN-1P3
ATTAIN-2P3
ACHIEVE-1P3
ACHIEVE-3P3
ACHIEVE-5P3
ACHIEVE-2P3
ATTAIN-OSAP3
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)P3
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 DiabetesP3
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related ComorbidityP3
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 DiabetesP3
ATTAIN-OA PAINP3
RESTRAIN-SUIP3
ATTAIN-PADP3
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)P3
semaglutide
SUSTAIN™P3
SUSTAINP3
A Study of Efinopegdutide (MK-6024) in Participants With Nonalcoholic Fatty Liver Disease (NAFLD) (MK-6024-001)P2
Research Study on Whether a Combination of 2 Medicines (NNC0194 0499 and Semaglutide) Works in People With Non-alcoholic Steatohepatitis (NASH)P2
SEMPATICOP2
OASIS 4P3
Trial to Learn About the Study Medicine (PF-07081532) and Rybelsus in People With Type 2 Diabetes and Separately PF-07081532 in People With ObesityP2
REDEFINE 1P3
A Research Study to See How Semaglutide Helps People With Excess Weight and Type 2 Diabetes Lose WeightP3
Efficacy and Safety of Semaglutide Injection vs Ozempic® in Patients With Type 2 DiabetesP3
Impact GLP-1 Agonists Following BariatricP4
SOLSTICEP2
Efficacy and Safety of Semaglutide for Weight Loss in Overweight or Obese Adults in Bangladesh With or Without Type 2 Diabetes MellitusP3
A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or TirzepatideP2
A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist UseP3
AMAZE 8P3
Upcoming readouts
13 ahead · 2 drugs
Select a trial to load its full ClinicalTrials.gov record.
Head to head
Registered phase 2–4 trial activity for each drug, computed from live ClinicalTrials.gov data.
orforglipronGLP-1 & incretin therapies
16
Phase 3 trials
4
Actively recruiting
Nov 2026
Next phase 3 readout
semaglutide (Ozempic / Wegovy)GLP-1 & incretin therapies
16+
Major trials tracked
9
Phase 3 trials
3
Actively recruiting
Dec 2026
Next phase 3 readout
Key trials across both drugs
Top 16 registered phase 2–4 trials across orforglipron and semaglutide, ordered by phase and status. Each links to its full ClinicalTrials.gov record.
| Drug | Trial | Title | Phase | Status | Primary completion |
|---|---|---|---|---|---|
| semaglutide | NCT06132477 | Impact GLP-1 Agonists Following Bariatric | Phase 4 | Recruiting | Jul 2028 |
| semaglutide | NCT07446439 | A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use | Phase 3 | Recruiting | Dec 2026 |
| orforglipron | NCT07202884 | RESTRAIN-SUI: A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity… | Phase 3 | Recruiting | Mar 2028 |
| orforglipron | NCT07153471 | ATTAIN-OA PAIN: A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthriti… | Phase 3 | Recruiting | Apr 2028 |
| orforglipron | NCT07223593 | ATTAIN-PAD: Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease | Phase 3 | Recruiting | Jun 2028 |
| orforglipron | NCT07241390 | A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Ca… | Phase 3 | Recruiting | Aug 2031 |
| semaglutide | NCT05567796 | REDEFINE 1: A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight | Phase 3 | Active, not recruiting | Oct 2024 |
| semaglutide | NCT06616961 | Efficacy and Safety of Semaglutide for Weight Loss in Overweight or Obese Adults in Bangladesh W… | Phase 3 | Not yet recruiting | Feb 2025 |
| orforglipron | NCT05869903 | ATTAIN-1: A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight… | Phase 3 | Active, not recruiting | Jul 2025 |
| orforglipron | NCT06649045 | ATTAIN-OSA: A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or O… | Phase 3 | Active, not recruiting | Nov 2026 |
| orforglipron | NCT06993792 | A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With a… | Phase 3 | Active, not recruiting | Aug 2027 |
| orforglipron | NCT06972459 | A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One … | Phase 3 | Active, not recruiting | Aug 2027 |
| orforglipron | NCT06972472 | A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabet… | Phase 3 | Active, not recruiting | Aug 2027 |
| orforglipron | NCT06948422 | A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or … | Phase 3 | Active, not recruiting | Sept 2027 |
| semaglutide | NCT07400107 | AMAZE 8: AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semagluti… | Phase 3 | Not yet recruiting | Dec 2028 |
| semaglutide | NCT02207374 | SUSTAIN™: A Trial Comparing the Safety and Efficacy of Semaglutide Once Weekly in Monotherapy or in Combin… | Phase 3 | Completed | Feb 2016 |
Individual pipelines and other comparisons
FAQ
- How do the orforglipron and semaglutide clinical pipelines compare?
- ClinicalTrials.gov currently lists 16+ phase 2–4 trials for orforglipron and 16+ for semaglutide. The timeline above plots both side by side and refreshes daily.
- Where does this data come from?
- All trial data is sourced from ClinicalTrials.gov (CTGov) and refreshed on this page daily. ComplyRx does not add efficacy or superiority claims; the comparison shows registered trial activity only.
- Can I add more drugs to the comparison?
- Yes. The tool above compares up to five drugs on one timeline, with PNG and PDF export. Add any competitor in the search box.